

### IIIM AF-01:

It is another follow up lead molecule based on bicyclic nitroimidazole structure with potent anti-TB activity. IIIM AF-01 is analogue of IIIM-019 active against resistant, replicating as well as non-replicating M. tb. It has improved solubility and also have promising pharmacokinetic profile. It showed very good *in vivo* efficacy in aerosol model of mice. It has shown good metabolic stability in RLM (85 % remaining after 30 minute) and also shown safety in Ames test. This lead is presently under further detailed pre-clinical studies.